Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,660 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Radium-223 international early access program: results from the Spanish subset.
Carles J, Méndez MJ, Pinto Á, Sáez MI, Arranz JA, Maroto P, López-Criado P, Mellado B, Donas JG, Hernando S, León L, Del Alba AG, Laínez N, Esteban E, Reynés G, Pérez-Gracia JL, Germà JR, López-Brea M, Pérez-Valderrama B, Moretones C, Castellano D. Carles J, et al. Among authors: pinto a. Future Oncol. 2018 Jan;14(1):41-50. doi: 10.2217/fon-2017-0297. Epub 2017 Dec 13. Future Oncol. 2018. PMID: 29232987 Clinical Trial.
Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
Puente J, González-Del-Alba A, Sala-Gonzalez N, Méndez-Vidal MJ, Pinto A, Rodríguez Á, Cuevas Sanz JM, Muñoz Del Toro JR, Useros Rodríguez E, García García-Porrero Á, Vázquez S. Puente J, et al. Among authors: pinto a. BMC Cancer. 2019 Aug 5;19(1):766. doi: 10.1186/s12885-019-5974-9. BMC Cancer. 2019. PMID: 31382926 Free PMC article.
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
Khalaf DJ, Aragón IM, Annala M, Lozano R, Taavitsainen S, Lorente D, Finch DL, Romero-Laorden N, Vergidis J, Cendón Y, Oja C, Pacheco MI, Zulfiqar M; PROREPAIR-B investigators; Gleave ME, Wyatt AW, Olmos D, Chi KN, Castro E. Khalaf DJ, et al. Ann Oncol. 2020 Sep;31(9):1186-1197. doi: 10.1016/j.annonc.2020.06.006. Epub 2020 Jun 20. Ann Oncol. 2020. PMID: 32574722 Free article. Clinical Trial.
Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy.
Viñal D, Gutierrez-Sainz L, Martinez D, Garcia-Cuesta JA, Pedregosa J, Villamayor J, Ostios L, Sanchez-Cabrero D, Higuera O, Pinto A, Rodriguez-Salas N, Espinosa E, de Castro J, Feliu J. Viñal D, et al. Among authors: pinto a. Clin Transl Oncol. 2021 Jun;23(6):1185-1192. doi: 10.1007/s12094-020-02509-1. Epub 2020 Nov 23. Clin Transl Oncol. 2021. PMID: 33226553
4,660 results